Bioceres Crop Solutions Announces Changes to Board of Directors
ROSARIO, Argentina--(BUSINESS WIRE)--Bioceres Crop Solutions Corp. (NASDAQ: BIOX) (the "Company"), a leader in the development and commercialization of productivity solutions designed to regenerate agricultural ecosystems while making crops more resilient to climate change, today announced changes to the composition of its Board of Directors.
Noah Kolatch and Scott Crocco are being appointed to the Company's Board of Directors with effect from June 24, 2025.
Noah Kolatch is a Principal at Jasper Lake LLC, a family investment office that invests across public and private markets. Prior to joining Jasper Lake, Mr. Kolatch was a Partner at Solel Partners, a Boston-based investment firm focused on public equity and credit investments. Mr. Kolatch graduated summa cum laude from Columbia College with a BA in biochemistry.
Scott Crocco is a seasoned executive with over three decades of experience in finance and operations across public and private companies. Mr. Crocco was CFO of Air Products & Chemicals, Inc. (NYSE: APD), where he led corporate restructuring and portfolio transformation, and later served as Chief Financial Officer of Imperial Dade, a private equity-backed distributor. Mr. Crocco holds a BS in Electrical Engineering from Bucknell University and an MBA from Cornell University.
Gloria Montaron Estrada, who has served as a Director since February 2019, and Keith McGovern, who has served as a Non-Executive Director since July 2022, have each resigned from the Company's Board of Directors with effect from June 24, 2025. The Company deeply appreciates the service of these outgoing Directors, each of whom offered valuable experience and expertise that benefitted the Company and its shareholders.
"On behalf of our Board, our Company, and personally, I would like to express our deepest gratitude to Gloria and Keith, for their tenures with us. Gloria has been with Bioceres since before our public listing, initially as General Counsel and then as Board Member. She played a pivotal role in shaping our legal and regulatory strategy, including key milestones such as the Rizobacter acquisition and our IPO. Keith joined the Board more recently, following our acquisition of Marrone Bio. His insights have, among other things, helped us maintain a grounded, farmer-centric perspective on innovation and go-to-market efforts, while reinforcing our focus on operational excellence.
As we look ahead, we are pleased to welcome Noah and Scott to our Board, as we enter a new chapter in Bioceres' trajectory. Noah has followed our Company closely since it became public and has been a committed investor at critical moments, helping us achieve key milestones such as the acquisition of Marrone Bio. Scott's 31-year trajectory in Air Products speaks for itself. Scott helped APD become one of the most profitable companies in its industry, with a strong focus on cash flow, strategic capital deployment, and global expansion. We are confident that the deep experience, strategic insight and shared commitment of our new Board members will help us further refine our strategy and deliver value to shareholders and partners,' said Federico Trucco, the Company's Chief Executive Officer.
Enrique Lopez Lecube, the Company's Chief Financial Officer and member of the Company's senior management team, will rotate off the Company's Board of Directors. The resulting vacancy will be filled by Milen Marinov, the Company's Chief Commercial Officer and member of the Company's senior management team. These changes will also be effective from June 24, 2025.
The above described changes to the composition of the Company's Board of Directors have been agreed as part of the Company entering into (1) an amendment to a note purchase agreement pursuant to which, in August 2022, it had issued secured guaranteed convertible notes to Jasper Lake Ventures One LLC, Redwood Enhanced Income Corp. and Liminality Partners LP and (2) an amendment to the note purchase agreement pursuant to which, in August 2022, it had issued secured guaranteed notes to Solel-Bioceres SPV, L.P. A summary of the terms of these amendments has been provided in a Form 6-K furnished by the Company to the Securities and Exchange Commission on June 18, 2025, which summary is qualified by reference to the full text of the amendment, which has been furnished as an exhibit to such Form 6-K, which can be accessed at www.sec.gov.
About Bioceres Crop Solutions Corp.
Bioceres Crop Solutions Corp. (NASDAQ: BIOX) is a leader in the development and commercialization of productivity solutions designed to regenerate agricultural ecosystems while making crops more resilient to climate change. To do this, Bioceres' solutions create economic incentives for farmers and other stakeholders to adopt environmentally friendlier production practices. The Company has a unique biotech platform with high-impact, patented technologies for seeds and microbial ag-inputs, as well as next generation crop nutrition and protection solutions. Through its HB4 program, the Company is bringing digital solutions to support growers' decisions and provide end-to-end traceability for production outputs. For more information, visit here.
Forward-Looking Statements
This communication includes 'forward-looking statements' within the meaning of the 'safe harbor' provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as 'forecast,' 'intend,' 'seek,' 'target,' 'anticipate,' 'believe,' 'expect,' 'estimate,' 'plan,' 'outlook,' and 'project' and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements are based on management's reasonable current assumptions, expectations, plans and forecasts regarding the Company's current or future results and future business and economic conditions more generally. Such forward-looking statements involve risks, uncertainties and other factors, which may cause the actual results, levels of activity, performance or achievement of the Company to be materially different from any future results expressed or implied by such forward-looking statements, and there can be no assurance that actual results will not differ materially from management's expectations or could affect the Company's ability to achieve its strategic goals, including factors that are described in the sections entitled 'Risk Factors' in the Company's Securities and Exchange Commission filings updated from time to time. The preceding list is not intended to be an exhaustive list of all of our forward-looking statements. Therefore, you should not rely on any of these forward-looking statements as predictions of future events. All forward-looking statements contained in this release are qualified in their entirety by this cautionary statement. Forward-looking statements speak only as of the date they are or were made, and the Company does not intend to update or otherwise revise the forward-looking statements to reflect events or circumstances after the date of this release or to reflect the occurrence of unanticipated events, except as required by law.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Post
an hour ago
- New York Post
Another buyer has made offer for Rays in potential twist
Another potential Rays buyer has thrown a hat in the ring. Trip Miller, the founder of a Memphis hedge fund, is the latest to join the billionaire race to own the Rays as he created a group that made an all-cash offer to Rays owner Stu Sternberg, according to The Athletic. 'We made an offer last week,' Miller said, per The Athletic. 'We have had contact with the club over the past month, specifically about our offer. 4 Rays' current owner, Stuart Sternberg, answered reporters' questions in March. Kim Klement Neitzel-Imagn Images 'If there is an exclusivity period that expires soon, and I don't know when it expires, we would welcome the opportunity to have a deeper discussion with the Rays about our offer.' It was reported Wednesday that Sternberg was in 'advanced talks' to sell the franchise with a group led by Jacksonville homebuilder Patrick Zalupski having executed a letter of intent to purchase the club. 4 Patrick Zalupski is the founder, chairman and CEO of Dream Finders Homes, a Florida-based homebuilder. University of Florida Zalupski's group's offer was reported to be $1.7 billion, according to Sportico. As for Miller's offer, he did not reveal the number but included that he and his group are willing to raise the number if necessary. The Rays are currently in need of a new stadium as they can't play at Tropicana Field after the stadium sustained damage from Hurricane Milton in October 2024. Tampa Bay has instead played at George M. Steinbrenner Field in Tampa — home to the Yankees' spring training and Low-A team. 4 Tropicana Field was ravaged by Hurricane Milton in October 2024. AFP via Getty Images The stadium issue is something that MLB is hoping a new owner would solve, as Sternberg had a deal in place to begin building a new 30,000-capacity stadium in downtown St. Petersburg before the plans ended because of financing delays. 'The league, that's what they're looking for — someone who can not only buy the club but solves the stadium problem,' Miller said. While finding a new stadium is a priority, relocating out of Central Florida is seemingly not an option. 4 Rays legend Evan Longoria puts on a jersey after signing an honorary one-day contract, alongside current Rays owner Stu Sternberg. AP 'This is not a relocation play to another state,' Miller said. 'You won't see the Rays relocating out of Central Florida, whether it was our group or another group.' Miller said that Orlando is not out of the realm of possibilities for relocation and that, all in all, the total investment for the team and a new stadium will be more than $3 billion.
Yahoo
an hour ago
- Yahoo
Why Advanced Micro Devices Stock Moved Higher Today
AMD stock jumped early in today's trading, but it gave up most of its gains as the market focused on risk factors for the tech sector and broader market. Investors are seeing signs that AMD is positioned to rack up wins in the artificial intelligence (AI) processor space. AMD's new AI processor and server products could deliver significant wins, but geopolitical dynamics and other factors could still create volatility for the stock. 10 stocks we like better than Advanced Micro Devices › Advanced Micro Devices (NASDAQ: AMD) stock ended Friday's trading in the green, despite pullbacks following a pop early in the session. The company's share price closed out the day up 1.1%, but it had been up as much as 4.7% earlier in the session. Meanwhile, the S&P 500 (SNPINDEX: ^GSPC) fell 0.2% in the daily session, and the Nasdaq Composite (NASDAQINDEX: ^IXIC) fell 0.5%. Thanks to rising excitement surrounding the company's position in artificial intelligence (AI), AMD stock opened today's trading with a big gain. The company's share price still advanced in the daily session, but it lost some ground as investors weighed new export restrictions for semiconductor technologies and the risk of escalating conflict in the Middle East. AMD stock has seen wild fluctuations over the last couple of years in conjunction with shifting expectations for the company's standing and market opportunity in the AI space. Following the Advancing AI 2025 conference hosted by the hardware specialist last week, market sentiment surrounding the stock has become significantly more bullish. At the conference AMD profiled its recently launched Instinct MI350 graphics processing unit (GPU) and its new server product for data centers. The company also announced that it had entered into a new deal to supply OpenAI with processing hardware, and its indications suggest that it may have also reached a new deal with Amazon. AMD appears to be making some laudable progress in the AI hardware market. While the company may continue to play second fiddle to Nvidia in the high-end data center GPU market, it will likely still have opportunities to score some big wins in the space. On the other hand, AMD stock could see high levels of volatility in the near term. Tech stocks wavered today following news that the Trump administration was implementing new bans on tech exports to China, and the market is also on edge about the possibility that the U.S. could get involved in the conflict between Israel and Iran. So even though AMD's AI growth bets appear to be moving in the right direction, there are other big catalysts that could shape stock performance in the near term. Before you buy stock in Advanced Micro Devices, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Advanced Micro Devices wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $659,171!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $891,722!* Now, it's worth noting Stock Advisor's total average return is 995% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Keith Noonan has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Advanced Micro Devices, Amazon, and Nvidia. The Motley Fool has a disclosure policy. Why Advanced Micro Devices Stock Moved Higher Today was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Vertex Presents Positive Data for Zimislecel in Type 1 Diabetes at the American Diabetes Association 85th Scientific Sessions
– Results from the study continue to demonstrate the transformative potential of zimislecel with consistent and durable patient benefit – – All 12 patients with at least one year of follow-up who received a full dose of zimislecel as a single infusion achieved ADA-recommended target HbA1c levels <7% and >70% time-in-range (70-180 mg/dL), and 10/12 patients were insulin free – – Data presented at ADA simultaneously published in the New England Journal of Medicine – – Vertex to host investor webcast tonight, June 20, 2025, at 7:15 p.m. CT / 8:15 p.m. ET – BOSTON, June 20, 2025--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced simultaneous presentation and publication of updated data from the Phase 1/2 portion of the Phase 1/2/3 FORWARD-101 clinical trial of zimislecel (VX-880), an investigational stem cell-derived, fully differentiated islet cell therapy, in people with type 1 diabetes (T1D) with impaired hypoglycemic awareness and severe hypoglycemic events (SHEs). The data were featured in an oral presentation at the American Diabetes Association (ADA) annual conference in Chicago as part of the symposium, "Innovation and Progress in Stem Cell-Derived Islet-Cell Replacement Therapy," from 6:15-6:30 p.m. CT (abstract 2025-A-1921) and published online by the New England Journal of Medicine. The data are from 12 patients who received the full dose of zimislecel as a single infusion and were followed for at least one year, as of October 2024. Results from the study to date continue to demonstrate the transformative potential of zimislecel with consistent and durable patient benefit with longer follow-up. All 12 participants: Demonstrated engraftment with glucose-responsive endogenous C-peptide production, which was durable through one year of follow-up. Achieved the ADA targets of HbA1c <7% and time in range of >70%. Were free of SHEs from day 90 onwards. Had a reduction in exogenous insulin use (mean reduction in daily insulin dose: 92%). 10/12 (83%) no longer required exogenous insulin at Month 12. Achieved the Phase 1/2 primary endpoint of elimination of SHEs with HbA1c <7%. Zimislecel continues to be generally well tolerated. Most adverse events (AEs) were mild or moderate, and there were no serious AEs related to zimislecel treatment. As previously reported, two patient deaths occurred, both unrelated to treatment with zimislecel. The safety profile is generally consistent with the immunosuppressive regimen used in the study, the infusion procedure, and complications from long-standing diabetes. "These data on the first fully differentiated, stem cell-derived, off-the-shelf islet cell therapy continue to be unprecedented. The magnitude, consistency and durability of the results from all 12 patients with more than one year of follow-up reinforce the transformative potential of zimislecel for people living with T1D complicated by severe hypoglycemia," said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer at Vertex. "We are excited to complete enrollment and dosing in the Phase 1/2/3 Program and look forward to potential regulatory submissions next year." "It's remarkable to see 12 out of 12 patients with baseline HbA1c above 7% and multiple severe hypoglycemic events reach consensus targets for glycemic control by both HbA1c and time in range as well as elimination of severe hypoglycemic events," said Michael R. Rickels, M.D., M.S., Medical Director, Pancreatic Islet Cell Transplant Program, Willard and Rhoda Ware Professor in Diabetes and Metabolic Diseases, Presenting Author and Steering Committee Co-Chair for the zimislecel clinical program, and author on the New England Journal of Medicine paper. "As I think about my patients and the unmet need in the type 1 diabetes community, the results we've seen so far for restoring endogenous insulin secretion with a stem cell-derived islet therapy bring me hope and confidence for a transformative treatment option for individuals with type 1 diabetes in the not-so-distant future." About Type 1 DiabetesT1D results from the autoimmune destruction of insulin-producing beta cells in pancreatic islets. Insulin deficiency results in hyperglycemia and can lead to acute life-threatening complications such as diabetic ketoacidosis. People with T1D are reliant on lifelong treatment with exogenous insulin that requires careful monitoring of blood glucose levels. Even with the availability of advanced exogenous insulin delivery and glucose monitoring systems, people with T1D can have periods of very low and very high blood sugar levels. Exogenous insulin has a narrow therapeutic range and carries an inherent risk of causing low blood sugar levels or hypoglycemic events, which can potentially result in arrhythmias, seizures, coma and even death. Due to the limitations and complexities of exogenous insulin treatment, it can be difficult for people with T1D to achieve and maintain good glucose control. Exposure to prolonged periods of high blood glucose levels, or hyperglycemia, can lead to long-term complications such as nerve damage, kidney disease/failure, eye disease (including vision loss), cardiovascular disease, stroke and even death. HbA1c is a measure of average blood glucose over the most recent ~2-3 months, and the consensus guidance is to maintain an HbA1c of <7% to reduce the risk of long-term complications; only ~1 in 4 people with T1D globally meet this clinical target. Current standards of care do not address the underlying cause of the disease and leave people with T1D susceptible to both hypo- and hyperglycemia and their associated morbidity and mortality. There is no cure for T1D. About ZimislecelZimislecel (VX-880) is an investigational allogeneic stem cell-derived, fully differentiated, insulin-producing islet cell therapy manufactured using proprietary technology. Zimislecel is being evaluated for patients who have T1D with impaired hypoglycemic awareness and severe hypoglycemia. Zimislecel has the potential to restore the body's ability to regulate glucose levels by restoring pancreatic islet cell function, including glucose-responsive insulin production. Zimislecel is delivered by an infusion into the hepatic portal vein and requires chronic immunosuppressive therapy to protect the islet cells from immune rejection. The zimislecel trial has expanded to additional sites that are currently active and enrolling in the U.S., Canada and Europe. Zimislecel has been granted Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations from the U.S. Food and Drug Administration, Priority Medicines (PRIME) designation from the European Medicines Agency (EMA), and has secured an Innovation Passport under the Innovative Licensing and Access Pathway (ILAP) from the UK Medicines and Healthcare products Regulatory Agency (MHRA). Zimislecel is investigational and has not been approved by health authorities globally. About VertexVertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases and conditions. The company has approved therapies for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain, and it continues to advance clinical and research programs in these areas. Vertex also has a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy, primary membranous nephropathy, autosomal dominant polycystic kidney disease, type 1 diabetes and myotonic dystrophy type 1. Vertex was founded in 1989 and has its global headquarters in Boston, with international headquarters in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia, Latin America and the Middle East. Vertex is consistently recognized as one of the industry's top places to work, including 15 consecutive years on Science magazine's Top Employers list and one of Fortune's 100 Best Companies to Work For. For company updates and to learn more about Vertex's history of innovation, visit or follow us on LinkedIn, Facebook, Instagram, YouTube and X. Special Note Regarding Forward-Looking StatementsThis press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, (i) statements by Carmen Bozic, M.D., and Michael R. Rickels, M.D., M.S., in this press release, (ii) plans, expectations for, and the potential benefits of zimislecel, (iii) expectations for the Phase 1/2/3 clinical trial for zimislecel, including expectations for the trial to complete enrollment and dosing, and (iv) plans for potential regulatory submissions next year. While Vertex believes the forward-looking statements contained in this press release are accurate, these forward-looking statements represent the company's beliefs only as of the date of this press release and there are a number of risks and uncertainties that could cause actual events or results to differ materially from those expressed or implied by such forward-looking statements. Those risks and uncertainties include, among other things, that data from a limited number of patients may not be indicative of final clinical trial results, that data from the company's research and development programs may not support registration or further development of its potential medicines in a timely manner, or at all, due to safety, efficacy, that timelines for regulatory submissions may be longer than anticipated, and other risks listed under the heading "Risk Factors" in Vertex's most recent annual report and subsequent quarterly reports filed with the Securities and Exchange Commission at and available through the company's website at You should not place undue reliance on these statements, or the scientific data presented. Vertex disclaims any obligation to update the information contained in this press release as new information becomes available. (VRTX-GEN) Investor Event and Webcast Vertex will host an investor event on Friday, June 20, 2025, at 7:15 p.m. CT/8:15 p.m. ET, in Chicago, to discuss the positive zimislecel data in type 1 diabetes. A live webcast of the presentation and Q&A portions can be accessed through the Investor Relations section of Vertex's website at An archived webcast will be available on the company's website. View source version on Contacts Vertex Pharmaceuticals IncorporatedInvestors: InvestorInfo@ Media: mediainfo@ orInternational: +44 20 3204 5275
